Search

EHA Statement of Solidarity with Ukraine

The European Hematology Association (EHA) is deeply concerned about the situation in Ukraine, the plight of the civilian population, and the damage to healthcare infrastructures.

Read more

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

EHA Meetings

Welcome to the overview of upcoming EHA meetings. More information regarding the meetings is available on the individual meeting pages which will be regularly updated.  

Read more

International CML adherence survey launched

The drivers behind non-adherence, a highly prevalent problem in oral cancer treatments but also in many other diseases like diabetes, are not well understood to date.

Read more

EHA-SWG Scientific Meeting "Patient-centered Geriatric Hematology"

EHA & the EHA Scientific Working Group on Hematology and Aging are happy to announce their recent collaboration in organizing a virtual meeting program providing delegates with the latest insights in the field of geriatric hematology, presented by leading hematologists.

Read more